New videos !!
Don't forget to subscribe !!
MSRV Retrovirus, phase 2
-
Fred1208
- Family Member
- Posts: 62
- Joined: Sat Nov 07, 2009 3:00 pm
- Location: Yvelines, France
- Contact:
Re: MSRV Retrovirus, phase 2
Stay tuned !!
The new revolution is coming regarding yhe understanding of auto-immune deseases !!
For the first time, MS process could be STOPPED.
http://www.geneuro.com/data/documents/2 ... ion-MP.pdf
The new revolution is coming regarding yhe understanding of auto-immune deseases !!
For the first time, MS process could be STOPPED.
http://www.geneuro.com/data/documents/2 ... ion-MP.pdf
-
Fred1208
- Family Member
- Posts: 62
- Joined: Sat Nov 07, 2009 3:00 pm
- Location: Yvelines, France
- Contact:
Re: MSRV Retrovirus, phase 2
Genuero Presentation: Defeating neurodegeneration through HERVs
April 2021
http://www.geneuro.com/data/documents/2 ... tation.pdf
April 2021
http://www.geneuro.com/data/documents/2 ... tation.pdf
-
Fred1208
- Family Member
- Posts: 62
- Joined: Sat Nov 07, 2009 3:00 pm
- Location: Yvelines, France
- Contact:
Re: MSRV Retrovirus, phase 2
Tommrrow 6 PM swiss time
webinar, should be in english, subscriibe here :
https://register.gotowebinar.com/regist ... 5759504651
webinar, should be in english, subscriibe here :
https://register.gotowebinar.com/regist ... 5759504651
Re: MSRV Retrovirus, phase 2
Here's an interesting write-up on endogenous retroviruses.
https://encyclopedia.thefreedictionary. ... retrovirus
https://encyclopedia.thefreedictionary. ... retrovirus
Re: MSRV Retrovirus, phase 2
Hello, here is an update concerning the extension study of the Protect-MS study with temelimab, dd 09/21/2021. This extension study allows the patients, who already have had 12 infusions, to continue the treatment with temelimab. The results of the Protect-MS study are still expected Q1 2022.
"GeNeuro announces that a first patient having finished the ProTEct-MS study at the Karolinska Institutet’s Academic Specialist Center has entered the study extension...."
Please read the full statement on the link below :
http://www.geneuro.com/en/technologies/rationale
"GeNeuro announces that a first patient having finished the ProTEct-MS study at the Karolinska Institutet’s Academic Specialist Center has entered the study extension...."
Please read the full statement on the link below :
http://www.geneuro.com/en/technologies/rationale
Re: MSRV Retrovirus, phase 2
Sorry, that's the wrong link. The good one is:
http://www.geneuro.com/data/news/GeNeur ... nt-ENG.pdf
http://www.geneuro.com/data/news/GeNeur ... nt-ENG.pdf
Re: MSRV Retrovirus, phase 2
Hello, the PRoTEct-MS study with temelimab is completed and the top-line results to be announced in march 2022 
:
https://www.businesswire.com/news/home/ ... er-31-2021
:https://www.businesswire.com/news/home/ ... er-31-2021
Re: MSRV Retrovirus, phase 2/RESULTS
Hello, good news ,
The results of the phase 2 trial with temelimab announced today:
"ProTEct-MS Phase 2 Trial Confirms Safety of Higher Doses of Temelimab and Synergistic Potential to Address Neurodegeneration on Top of Anti-inflammatory Treatment in Multiple Sclerosis..."
More here:
http://www.geneuro.com/data/news/GeNeur ... 1-2022.pdf
,The results of the phase 2 trial with temelimab announced today:
"ProTEct-MS Phase 2 Trial Confirms Safety of Higher Doses of Temelimab and Synergistic Potential to Address Neurodegeneration on Top of Anti-inflammatory Treatment in Multiple Sclerosis..."
More here:
http://www.geneuro.com/data/news/GeNeur ... 1-2022.pdf
Re: MSRV Retrovirus, phase 2
Hello,
Here's a link to the presentation of these top-line results:
http://www.geneuro.ch/data/documents/GN ... 22-ENG.pdf
Here's a link to the presentation of these top-line results:
http://www.geneuro.ch/data/documents/GN ... 22-ENG.pdf
Re: MSRV Retrovirus, phase 2
Hello,
Watch the comments of these results hereby, if you are interested
Watch the comments of these results hereby, if you are interested
Re: MSRV Retrovirus, phase 2
Hi,
These results have been presented at the ECTRIMS 2022 congress (10/27) in Amsterdam by dr Frederik Piehl, from the Karolinska Institutet in Sweden.
"GeNeuro’s ProTEct-MS Phase 2 Trial Data, Presented at the ECTRIMS 2022 Congress in Amsterdam, Confirms Synergistic Neuroprotective Potential of Temelimab in MS
Excellent safety profile and tolerability of higher doses of temelimab
Synergistic potential to treat neurodegeneration in addition to high-efficacy anti-inflammatory therapy in multiple sclerosis
Exploratory CSF biomarkers confirm MRI efficacy observations (...)"
From this link :
https://www.businesswire.com/news/home/ ... imab-in-MS
By the way temelimab is also been currently tested in a P2 clinical trial on the Post-Covid condition, a 6 months study:
https://clinicaltrials.gov/ct2/show/NCT ... w=2&rank=1
The longhaulers enroled must have the pHERV-w protein in the blood. --> In MS, this protein is in the brain and supposed to be responsible of the neurodegeneration.
Fingers crossed.
These results have been presented at the ECTRIMS 2022 congress (10/27) in Amsterdam by dr Frederik Piehl, from the Karolinska Institutet in Sweden.
"GeNeuro’s ProTEct-MS Phase 2 Trial Data, Presented at the ECTRIMS 2022 Congress in Amsterdam, Confirms Synergistic Neuroprotective Potential of Temelimab in MS
Excellent safety profile and tolerability of higher doses of temelimab
Synergistic potential to treat neurodegeneration in addition to high-efficacy anti-inflammatory therapy in multiple sclerosis
Exploratory CSF biomarkers confirm MRI efficacy observations (...)"
From this link :
https://www.businesswire.com/news/home/ ... imab-in-MS
By the way temelimab is also been currently tested in a P2 clinical trial on the Post-Covid condition, a 6 months study:
https://clinicaltrials.gov/ct2/show/NCT ... w=2&rank=1
The longhaulers enroled must have the pHERV-w protein in the blood. --> In MS, this protein is in the brain and supposed to be responsible of the neurodegeneration.
Fingers crossed.